Navigation Links
Anti-vomiting drug could prevent thousands of hospitalizations, save millions of dollars
Date:10/14/2010

CHAPEL HILL Two years ago, a study by University of North Carolina at Chapel Hill researchers found that an anti-vomiting drug called ondansetron helps reduce vomiting, the need for intravenous fluids and hospital admissions in children with acute gastroenteritis.

Now a new economic analysis led by Canadian researchers, in collaboration with Michael J. Steiner, MD, assistant professor of pediatrics at UNC, concludes that routinely giving ondansetron to children with gastroenteritis-induced vomiting would prevent thousands of hospitalizations and save millions of dollars each year.

"In the past, people always thought that ondansetron was so expensive that its use 'wasn't worth it.' Our findings challenge that belief and may change clinician decision-making as well as practice guidelines," Steiner said.

The new study was published online this week by the journal PLoS Medicine. The lead author is Stephen B. Freedman, MDCM, a pediatric emergency physician at The Hospital for Sick Children (SickKids) and assistant professor of pediatrics at the University of Toronto. Co-authors are Steiner and Kevin J. Chan, MD, also a pediatric emergency physician at SickKids.

"This study is the first to demonstrate that in addition to being clinically beneficial, the administration of oral ondansetron to children with dehydration and persistent vomiting secondary to gastroenteritis, is economically advantageous, making it a dominant treatment strategy," Freedman said.

Gastroenteritis is an infection, often caused by a virus, that causes vomiting and diarrhea. It is popularly called "stomach flu" and is a very common ailment in children during the winter months. Persistent vomiting from acute gastroenteritis can be very frightening to children and their families and also poses a risk of dehydration.

In many cases gastroenteritis in children can be managed effectively with oral fluids, including oral rehydration therapy, but some cases are severe enough to require hospital admission for intravenous fluids. However, current practice guidelines do not recommend the use of ondansetron, in part because there was a lack of clear evidence that the treatment is cost effective.

To answer this question, study authors used a type of statistical analysis, called decision tree analysis, to compare the costs of treatment in the hospital emergency department setting both with and without ondansetron. Due to significant price differences between the U.S. and Canada, they conducted a separate analysis for each country.

They concluded that giving ondansetron to eligible children in the U.S. would prevent 29,246 intravenous insertions and 7,220 hospitalizations each year, with annual savings of $65.6 million to society and $61.1 million to payers of health care costs (including private insurance providers and Medicare and Medicaid). In Canada, the study concluded, ondansetron given routinely would prevent 4,065 intravenous insertions and 1,003 hospitalizations each year, with annual savings of $1.72 million (in Canadian dollars) to society and $1.18 million to payers of health care costs.


'/>"/>

Contact: Tom Hughes
tahughes@unch.unc.edu
919-966-6047
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. Premature Death Could Await Obese Kids
2. Six Other E. colis Could Be Lurking In Your Valentine Days Dinner
3. Tiny fruit fly could offer big clues in fight against obesity, researcher says
4. New Book Reveals How Qigong Could Be The Eastern Answer To Botox
5. Chocolate lovers could be lowering their risk of stroke: Study
6. Charging less for more effective treatments could reduce health care costs while improving health
7. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
8. UAB-led study shows simple steps could reduce stillbirths by up to 1 million
9. Most maternal deaths in sub-Saharan Africa could be avoided
10. Dolphins could be ideal model to study human cervical cancer, UF veterinarians say
11. New Technology Could Widen Reach of Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – is set to return to the esteemed Quaker Ridge Golf ...
(Date:5/4/2016)... York, NY (PRWEB) , ... May 04, 2016 ... ... leading private owners, developers and operators of commercial real estate proudly announced that ... 2015 Heart Health initiative. Team members portfolio-wide will continue Olshan Properties’ annual ...
(Date:5/4/2016)... ... May 04, 2016 , ... a2z, Inc. is ... and Canadian Association for Enterostomal Therapy (CAET) will be utilizing powerful and innovative ... to attendees and exhibitors for the 2016 WOCN Society & CAET Joint Conference—which ...
(Date:5/4/2016)... ... May 04, 2016 , ... All-Star ... created to assist the people of their local community. The agency pledges to ... community leaders. Their hope is to bring awareness to important local causes with ...
(Date:5/4/2016)... East Providence, Rhode Island (PRWEB) , ... May ... ... website was launched in April 2016. SS&A teamed up with one of the ... website. This legal information portal contains informative legal articles related to the law ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... Intec Pharma Ltd. (NASDAQ: NTEC ... the appointment of Pnina Strauss-Levy as Vice ... has 15 years of experience in clinical research and ... having supported the advancement of several products through the ... the United States and Europe ...
(Date:5/2/2016)... , May 2, 2016 Kalorama Information noted ... Medical Records) market in a recent white paper.  The ... Increased physician usage, a growing market are among the ... in Kalorama,s report EMR 2016: The Market ... Kalorama,s seventh complete study of the EMR industry, and ...
(Date:5/2/2016)... 2016  Celsion Corporation (NASDAQ: CLSN ), ... from the first cohort of patients in its ... Study) combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... In the first three patients dosed, GEN-1 plus ...
Breaking Medicine Technology: